I have to agree. I don’t want dividends and would rather
I have to agree. I don’t want dividends and would rather the monies buy back stock. As for a shelf offer. I believe we will sell our whole inventory as soon as we have results and would not need to sell any additional stock. We have approximately 2 billion in Vyrologix waiting for the first buyer. Hopefully that’s the US government.
Then I hope we get another 8-10 million doses on order right away with Samsung. That’s what was said by Nader. I hope a quick visit to South Korea allows a much bigger purchase using there new bioreactor... if there is one thing I expect from the OWS and the FDA is a quick approval of Samsung’s new bioreactors. That much is what should happen. Will it? I sure the hell hope so. Then there is the production facilities in Colorado for AGC that is suppose to be a big bioreactor facility. A little help by OWS and FDA for these facilities and were looking good for production to start. Ramping up with FDA Priority help can and will be a huge deal.
Lets unleash the Kraken that is Vyrologix and start the pathway back to normal times we all once knew. That’s my hope.
6
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Frontera Energy Announces First Quarter Financial Results Frontera Energy Corporation (TSX: FEC) has exciting news for its shareholders and interested investors. The Company is set to unveil its financial and operational results for the first quarter, wrapping up on March 31, 2025. This significant announcement will occur after the market closes on a forthcoming Thursday...
Continue Reading
Exploring the Global Market for Contrast Media Injectors The global market for contrast media injectors is on the verge of substantial growth, with projections indicating it will reach $2.1 billion in the coming years. This anticipated growth, at a compound annual growth rate (CAGR) of 7.8% from 2025 through 2033, is primarily driven by ongoing advances in technology and...
Continue Reading
Beth Wozniak's Recent Stock Sale at nVent Electric Beth Wozniak, Chair & CEO of nVent Electric (NYSE:NVT), executed a significant insider sale recently, as revealed in a new SEC filing. This transaction involved the offloading of 7,597 shares, with a total value of approximately $884,822. Such movements in stock ownership often pique the interest of investors, prompting...
Continue Reading
The Impact of Home Prices on the Upcoming Election As we approach the presidential election, the role that home prices play in shaping voter sentiments is becoming increasingly evident. Recent research has shown that fluctuations in the housing market can significantly affect how voters make their choices, particularly in crucial battleground states. Current Trends in...
Continue Reading
Iambic Therapeutics Welcomes Michael Secora as CFO and CDO Iambic Therapeutics has announced an important leadership change, appointing Michael Secora, Ph.D., as its Chief Corporate Development Officer and Chief Financial Officer. This decision comes as Iambic continues its commitment to pioneering novel medicines through its innovative AI-driven drug discovery platform....
Continue Reading